Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients | Zendy

Ahmet Çağkan İnkaya | Zendy; Emre Kara | Zendy; Nursel Çalık Başaran | Zendy; Taha Koray Şahin | Zendy; Oğuz Abdullah Uyaroğlu | Zendy; Ömrüm Uzun | Zendy; Serhat Ünal | Zendy

Open Access

Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients

Author(s) -

Ahmet Çağkan İnkaya,

Emre Kara,

Nursel Çalık Başaran,

Taha Koray Şahin,

Oğuz Abdullah Uyaroğlu,

Ömrüm Uzun,

Serhat Ünal

Publication year - 2021

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-2102-84

Subject(s) - medicine , surrogate endpoint , favipiravir , uric acid , covid-19 , betacoronavirus , intensive care medicine , virology , disease , outbreak , infectious disease (medical specialty)

To the editor, Favipiravir (FVP) was developed against the influenza virus infection and licensed for the treatment of influenza in Japan [1]. In addition to influenza viruses, FVP demonstrates a broad-spectrum activity against many RNA viruses including Ebola, Lassa, rabies, and severe fever with thrombocytopenia [2]. FVP exhibited a comparable in vitro efficacy against SARS-CoV-2 with remdesivir in a cell culture model [3].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research